Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients

Inclusion Criteria

• •Voluntary participation with documented informed consent.
• •Females aged ≥18 years.
• •Histological or cytological confirmed primary breast carcinoma.
• •Clinical diagnosis of cN3c.
• •Receipt of neoadjuvant therapy, guided by the attending physician and current treatment guidelines.
• •Did not achieve cCR in SCLN following neoadjuvant therapy.
• •Undergoing curative-intent breast cancer surgery post-neoadjuvant therapy.
• •Pathological evaluation of axillary lymph nodes post-surgery.
• •KPS score ≥80, with expected survival exceeding 2 years.
• •Complete healing of surgical incision without complications.
• •Negative pathological surgical margins.
• •Availability of hormonal receptor (ER/PR), HER2, and Ki-67 status for the primary breast lesion.
• •Pre-menopausal females required to practice contraception for at least one month prior to screening, maintaining contraception throughout the study and for a specified period post-study cessation.